drugset / Trial / NCT01208090

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01208090

Phase 2 Completed 326 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Timeline

Start
2010-10-31
Primary completion
2012-10-31
Completion
2012-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule 20 mg Oral
Subject Ponesimod Small molecule 40 mg Oral

Indications